Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Mega Cap Growth ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Vanguard Mega Cap Growth ETF trades at $88.82. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals.
| BMY | MGK | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $92.06 |
52-Week Low | $42.60 | $70.70 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MGK (Vanguard Mega Cap Growth ETF) trades at $87.69, down 1.54% today amid a bearish technical signal. The ETF maintains a concentrated portfolio of 69 large-cap growth stocks with heavy technology exposure and a low 0.05% expense ratio. Recent developments include a 1:5 stock split effective April 21, 2026, and potential addition of SpaceX following its recent IPO.
The ETF's concentrated mega-cap growth strategy offers strong long-term return potential but carries sector concentration risk. Technical indicators suggest near-term consolidation while fundamental strength in technology holdings supports the bullish long-term thesis. Investors should weigh the ETF's historical outperformance against its vulnerability to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
